Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 4/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23829840 | 1.00 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL8143846 | 1.00 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL23421926 | 0.83 | SLC7A5 (0.52) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL10618897 | 0.79 | PTGS1 (0.55) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL6832737 | 0.79 | PTGS1 (0.55) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Leucine SCHEMBL7423425 | 0.78 | SLC7A5 (0.75) | GRIK1GRIK2SLC7A5SLC1A1GRIA4 | |
| SCHEMBL564563 | 0.77 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL3044802 | 0.77 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL3145928 | 0.77 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL7366965 | 0.77 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001395-A2 | PREVENTION AND TREATMENT OF INFLUENZA WITH GLUTAMINE ANTAGONIST AGENTS | UNIVERSITY OF SOUTH CAROLINA (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060276438-A1 | Prevention and treatment of influenza with glutamine antagonist agents | UNIVERSITY OF SOUTH CAROLINA | 2006-12-07 | — | — | US | claimed |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-02-08 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3328375-B1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | UNIV JOHNS HOPKINS (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2022-08-04 | — | — | US | disclosed |
| CN-108135875-B | Methods and compositions for treating metabolic reprogramming disorders | 约翰霍普金斯大学 | 2021-12-31 | — | — | CN | disclosed |
| CN-108348492-B | Methods for cancer and immunotherapy using glutamine analogs | 约翰霍普金斯大学 | 2021-09-28 | — | — | CN | disclosed |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| EP-1220894-A1 | PRPP-AMIDOTRANSFERASE FROM PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-10 | — | — | EP | disclosed |
| US-6310093-B1 | ADMINISTERING, IN AMOUNT EFFECTIVE TO REDUCE DAMAGE TO NEURONAL CELLS, COMPOUND WHICH SELECTIVELY INHIBITS EXTRACELLULAR GLUTAMINASE RELATIVE TO GLUTAMINASE PRESENT IN INTACT CELLS AND IS IMPERMEABLE TO INTACT CELL MEMBRANES | ELAN PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2001027248-A1 | PRPP-AMIDOTRANSFERASE FROM NICOTIANA TABACUM | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-1999009825-A1 | METHOD OF PREVENTING NEURONAL DEATH | ELAN PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0607124-B1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH | HANDELMAN JOSEPH H (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0607124-A1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH. | HANDELMAN JOSEPH H (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0607124-A4 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH. | HANDELMAN JOSEPH H (US) | 1993-04-19 | — | — | EP | disclosed |
| US-5096911-A | Applying gamma-glutamyl transpeptidase inhibitor | GILLETTE COMPANY, THE A CORP. OF DELAWARE | 1992-03-17 | — | — | US | disclosed |
| WO-1992000069-A1 | ALTERATION OF RATE AND CHARACTER OF HAIR GROWTH | HANDELMAN, JOSEPH, H. (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | GRIK1 1056/4885GRIK2 1483/4885GRM1 87/4885 |
| US-20220241299-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | GRIK1 64/4885GRIK2 87/4885GRM1 20/4885 |
| US-20240408114-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | GLS, GLUL, ASNS | GRIK1 314/4885GRIK2 498/4885GRM1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.